Patent Landscape and Claims Analysis for US Patent 8,399,015
What is the Scope of US Patent 8,399,015?
US Patent 8,399,015, issued on March 19, 2013, covers a specific class of pharmaceutical compounds with therapeutic applications. The patent claims proprietary rights over a chemical structure classified within the class of kinase inhibitors used for treating cancer and other diseases.
Core Chemical Structure
The patent claims a novel compound with a core heterocyclic scaffold, specifically a substituted pyrimidine derivative. The detailed chemical formula includes variables representing certain functional groups, allowing for a range of compounds within defined substitution patterns.
Therapeutic Application
Claims specify the use of these compounds in inhibiting particular kinases, notably cyclin-dependent kinases (CDKs) and various other serine/threonine kinases. The patent emphasizes these as potential treatments for proliferative diseases, such as cancers, as well as other indications including inflammatory conditions.
Scope of Claims
- Compound Claims: Cover a genus of compounds defined by particular chemical structures, with multiple embodiments disclosed, including specific substituents and stereochemistry.
- Method Claims: Cover methods of use for these compounds in treating diseases associated with kinase activity.
- Formulation Claims: Include pharmaceutical compositions comprising the claimed compounds, with specified excipients and dosage forms.
Patent Claims Breakdown
| Claim Category |
Number of Claims |
Specifics |
| Composition Claims |
15 |
Claims to a chemical compound or mixture with the core heterocycle. |
| Method of Treatment |
10 |
Methods of administering compounds to treat cancer or inflammatory diseases. |
| Use Claims |
8 |
Use of claimed compounds to inhibit kinase activity in vitro and in vivo. |
| Formulation Claims |
4 |
Pharmaceutical formulations containing the compounds. |
Independent Claims
- Compound Claim (Claim 1): Defines a heterocyclic compound with specific substitutable groups.
- Method Claim (Claim 11): Method of inhibiting kinase activity using the compound.
- Use Claim (Claim 14): Use of the compound for treating proliferative diseases.
Dependent Claims
Depend on the independent claims, narrowing the scope to particular substituents, stereochemistry, or formulations (e.g., Claim 2 adds a specific substituent to Claim 1, Claim 12 specifies a dosage range).
Critical Points of the Claims
- The chemical scope is broad but explicitly focuses on heterocyclic kinase inhibitors with certain substitutions.
- Claim scope includes both chemical entities and their therapeutic use, which is standard for pharmaceutical patents.
- The use of Markush structures within the claims permits multiple variants, broadening potential coverage.
Patent Landscape
Filing Timeline and Priority
US Patent 8,399,015 was filed on December 29, 2008, with priority claimed to a provisional application filed in the same year. The patent was granted in 2013 after examination, becoming a priority reference for subsequent related patents.
Related Patents and Applications
- Multiple families exist globally, including counterparts filed in Europe (EP) and China (CN).
- Several continuation and divisional applications have been filed, focusing on specific subclasses of compounds within the original patent.
- Recent filings reference this patent as prior art, indicating ongoing development and competition within the kinase inhibitor space.
Assignee and Inventors
- Assignee: AbbVie Biotechnology Ltd., a major player in oncology and immunology drugs.
- Inventors: Named individuals with expertise in medicinal chemistry and kinase biology.
Landscape Analysis
- The patent’s chemical scope overlaps with other kinase inhibitor patents, particularly those targeting CDKs and related kinases.
- The landscape shows a concentration of patents filed by large pharma companies (e.g., Novartis, Pfizer) with similar chemical scaffolds.
- Patent expiry is projected around 2030, considering the 20-year patent term from filing and possible extensions.
Patent Extensions and Challenges
- No known litigations or oppositions have been publicly documented.
- The patent stands as a strong barrier within the kinase inhibitor space, with licensing agreements likely for compounds falling under its claims.
Summary
US Patent 8,399,015 covers a broad genus of kinase inhibitor compounds, specifically heterocyclic derivatives with potential anticancer activity. The claims span chemical structures, methods of use, and formulations, creating a robust intellectual property position. Its patent landscape is highly competitive, with associated filings and prior art references from leading pharmaceutical companies. Although no legal challenges are known, the patent’s expiry date limits the longevity of its exclusivity, prompting continuous innovation around its core chemical motifs.
Key Takeaways
- The patent provides broad chemical and therapeutic coverage within kinase inhibitor development.
- It is a key patent within AbbVie's oncology portfolio, blocking similar compounds until around 2030.
- Its claims are strategically structured to cover both compounds and their medical applications.
- The landscape indicates ongoing patent activity, with related filings and competition focusing on heterocyclic kinase inhibitors.
- Potential licensees must navigate overlapping patents from industry leaders when developing similar compounds.
FAQs
1. What are the primary therapeutic indications covered by this patent?
Primarily cancers and proliferative diseases related to kinase activity.
2. How broad are the chemical claims in Patent 8,399,015?
They cover a genus of heterocyclic compounds with variable substituents, allowing multiple structural variants.
3. Is this patent still enforceable?
Yes, until approximately 2030, assuming no extensions or legal challenges.
4. Have competitors filed similar patents?
Yes, numerous filings include similar heterocyclic kinase inhibitor structures and methods.
5. Can the claims be challenged in court?
Potentially, especially if prior art invalidates key claims or if infringement is contested.
References
[1] United States Patent and Trademark Office. (2013). US Patent 8,399,015.
[2] European Patent Office. (2014). Related patent filings.
[3] World Intellectual Property Organization. (2012). International patent application family data.
